Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro

Launched by PICTERUS AS · Mar 21, 2024

Keywords

ClinConnect Summary

The Intermountain Inpatient Bilirubin Decision Accuracy Study is researching a new tool called Picterus Jaundice Pro, which is used to measure bilirubin levels in newborns. Bilirubin is a substance in the blood that can cause jaundice, a yellowing of the skin and eyes in babies. This study aims to see how well this tool works in American infants, including both preterm (born before 35 weeks) and term (born after 35 weeks) babies, especially before and after they receive light therapy, a common treatment for jaundice.

To participate in this study, babies must be between 0 and 8 days old and free from any skin rashes, bruises, or other conditions that could affect the measurement. If your baby meets these criteria, they could be eligible to join the trial. Participants will have their bilirubin levels checked using the Picterus device, and the study will help determine if this smartphone-based method is a reliable way to monitor jaundice in newborns. This could lead to better and easier care for babies with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • the patient is free of skin rash, bruising, or other medical conditions that can interfere with transcutaneous measurement
• • (preterm) \< = 35 weeks gestational age
• • (term) \> 35 weeks gestational age
• • the patient has not been excluded by PI discretion.
• Exclusion Criteria:
• • Neonates will be excluded from participation if all four inclusion criteria listed above are not met.